A new research paper titled "BCAS1 defines a heterogeneous cell population in diffuse gliomas" has been published in Oncotarget. Oligodendrocyte precursor markers have become of great interest to ...

Credit: Jazz Pharmaceuticals. Modeyso is the first FDA-approved treatment for this rare brain tumor. Continued approval for this indication is contingent upon verification of clinical benefit in the ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Modeyso for patients with H3 K27M-mutant diffuse midline glioma. The therapy showed an overall ...

What Is Modeyso, and Why Does It Matter? Modeyso (dordaviprone) is a new oral medicine that treats a rare and aggressive brain tumor, called diffuse midline glioma (DMG), that has a tumor mutation ...

Dordaviprone has been granted Priority Review by the FDA for recurrent H3 K27M-mutant diffuse glioma, with a target action date of August 18. The drug has received Rare Pediatric Disease, Fast-Track, ...

DUBLIN, Aug. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ ...

Kelley Mack’s death at 33 is putting glioma under the spotlight. After news broke that The Walking Dead and 9-1-1 star had died on Saturday, August 2, fans were reminded that the actress was recently ...

Figure 2: BCAS1 + cells in diffuse gliomas are morphologically different from BCAS1 + cells in healthy brain tissue. Oligodendrocyte precursor markers have become of great interest to identify new ...